DDInter1042 DDInter580
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.
Dofetilide {u} (Compound) resembles {v} (Compound) Dronedarone
Dofetilide {u} (Compound) resembles {v} (Compound) Rosiglitazone
Dofetilide {u} (Compound) binds {v} (Gene) KCNH2
Dofetilide {u} (Compound) upregulates {v} (Gene) CASP7
Dofetilide {u} (Compound) downregulates {v} (Gene) CDCA4
Dofetilide {u} (Compound) causes {v} (Side Effect) Dyspnoea
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Dofetilide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Troglitazone
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Dofetilide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Octreotide
Dofetilide (Compound) resembles Dronedarone (Compound)
Dofetilide (Compound) resembles Rosiglitazone (Compound)
Dofetilide (Compound) binds KCNH2 (Gene)
Dofetilide (Compound) upregulates CASP7 (Gene)
Dofetilide (Compound) downregulates CDCA4 (Gene)
Dofetilide (Compound) causes Dyspnoea (Side Effect)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Troglitazone
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide